On Oct 31, major Wall Street analysts update their ratings for $AtriCure (ATRC.US)$, with price targets ranging from $36 to $60.
J.P. Morgan analyst Robbie Marcus maintains with a buy rating, and adjusts the target price from $30 to $40.
UBS analyst Danielle Antalffy maintains with a buy rating, and adjusts the target price from $35 to $40.
Oppenheimer analyst Suraj Kalia maintains with a buy rating, and adjusts the target price from $32 to $36.
Needham analyst Michael Matson maintains with a buy rating, and adjusts the target price from $34 to $40.
Stifel analyst Rick Wise maintains with a buy rating, and adjusts the target price from $26 to $36.
Furthermore, according to the comprehensive report, the opinions of $AtriCure (ATRC.US)$'s main analysts recently are as follows:
AtriCure's recent quarter was described as 'exciting,' surpassing sales expectations by 3.4%, indicating a robust performance. Even considering some impact from PFA, the MIS Ablation business's underperformance is seen as not detrimental to the company's sustained mid-teens growth outlook. AtriCure continues to focus on enhancing profitability and anticipates achieving positive cash flow in FY25.
AtriCure's third-quarter revenues reached $116M, marginally surpassing the anticipated $113M and consensus estimate of $112M. Analysts maintain a tactically constructive stance on AtriCure, noting a favorable risk/reward profile with the company trading at approximately 2.7 times FY25 sales compared to its small-cap MedTech peers, which average around 3.7 times.
Here are the latest investment ratings and price targets for $AtriCure (ATRC.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
